Chemokines in COPD: From Implication to Therapeutic Use

Area of Science:

• Pulmonary Medicine
• Immunology
• Cell Biology

Background:

• Chronic Obstructive Pulmonary Disease (COPD) is a major global health burden, ranking as the third leading cause of death worldwide.
• The lung's intricate structure involves constant interaction between structural and immune cells, influencing disease development.
• Both cell types express chemokines and receptors, responding to concentration gradient changes.

Purpose of the Study:

• To review the role of chemokines in COPD pathophysiology.
• To hypothesize that chemokine system dysregulation is crucial for COPD evolution during stable states and exacerbations.
• To highlight specific chemokine axes implicated in COPD.

Main Methods:

• Literature review of evidence on chemokine involvement in COPD.
• Analysis of cell-cell interactions and chemokine/receptor expression in pulmonary tissue.
• Focus on specific chemokine axes: CXCL8-CXCR1/2, CXCL9/10/11-CXCR3, CCL2-CCR2, and CXCL12-CXCR4.

Main Results:

• Chemokines and chemokine receptors are significantly impacted by cigarette smoke exposure and COPD exacerbations.
• Evidence suggests a critical role for dysregulated chemokine systems in COPD.
• Specific axes like CXCL8-CXCR1/2, CXCL9/10/11-CXCR3, CCL2-CCR2, and CXCL12-CXCR4 are particularly implicated.

Conclusions:

• Dysregulation of the chemokine system is a critical factor in COPD pathogenesis.
• Targeting chemokines and their receptors presents a promising therapeutic strategy for managing COPD.
• This approach could effectively control chronic inflammation and bronchial remodeling in COPD patients.